Detalhe da pesquisa
1.
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(9): 989-1001, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591293
2.
Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
Future Oncol
; 18(39): 4385-4397, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36656547
3.
The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade.
Anesth Analg
; 121(2): 366-72, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25902322
4.
Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression.
Br J Haematol
; 167(5): 664-70, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25160658
5.
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
J Thorac Oncol
; 18(6): 755-768, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37001859
6.
Chemosensitized radiosurgery for recurrent brain metastases.
J Neurooncol
; 110(2): 265-70, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22910852
7.
Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer.
Sci Rep
; 12(1): 17670, 2022 10 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36271096
8.
Characterizing the Shifting Real-World Treatment Landscape by PD-L1 Testing Status and Expression Level in Advanced Non-Small Cell Lung Cancer.
Adv Ther
; 39(10): 4645-4662, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35948845
9.
Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
Ther Adv Med Oncol
; 14: 17588359221105024, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35747163
10.
Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy.
Cancer Manag Res
; 14: 3191-3202, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36415537
11.
Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer.
Front Oncol
; 12: 1081729, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-37082098
12.
Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
Gynecol Oncol
; 114(3): 410-4, 2009 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-19520420
13.
Response to Letter to the Editor.
J Thorac Oncol
; 18(7): e74-e75, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37348997
14.
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
J Clin Oncol
; 28(12): 2051-7, 2010 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20308655
15.
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
J Clin Oncol
; 27(35): 5906-10, 2009 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19858391
16.
A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma.
Invest New Drugs
; 25(2): 155-9, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16957835